Viral escape from CD8 + cytotoxic T lymphocyte responses correlates with disease progression and 6 represents a significant challenge for vaccination. Here, we demonstrate that CD8 + T cell 7 recognition of the naturally occurring MHC-I-restricted LCMV-associated immune escape variant 8 Y4F is restored following vaccination with a proline-altered peptide ligand (APL). The APL 9 increases MHC/peptide (pMHC) complex stability, rigidifies the peptide and facilitates T cell 10 receptor (TCR) recognition through reduced entropy costs. Structural analyses of pMHC 11 complexes before and after TCR binding, combined with biophysical analyses, revealed that 12 although the TCR binds similarly to all complexes, the p3P modification alters the conformations 13 of a very limited amount of specific MHC and peptide residues, facilitating efficient TCR 14 recognition. This approach can be easily introduced in peptides restricted to other MHC alleles, 15 and can be combined with currently available and future vaccination protocols in order to prevent 16 viral immune escape.
altered epitopes that re-establish and enhance significantly CD8 + T cell recognition of a naturally 22 occurring viral immune escape variant. Biophysical and structural analyses provide a clear 23 understanding of the molecular mechanisms underlying this reestablished recognition. We 24 believe that this approach can be implemented to currently available or novel vaccination 25 approaches to efficiently restore T cell recognition of virus escape variants to control disease 26 progression. To our knowledge, previous use of wild-type and escape epitopes in vaccination experiments has 54 not provided efficient CTL responses against MHC-restricted viral escape variants [14, 15] . 55 Therefore, the design of altered peptide ligands (APLs) that could promote such responses would 56 represent a crucial step towards the development of efficient vaccines [16] . Although our 57 understanding of the interactions between TCRs and pMHC has increased dramatically, the impact 58 of individual peptide modifications on TCR recognition remains difficult to predict. Even subtle 59 peptide alterations can significantly impact on pMHC stability, and impair or abolish T cell 60 recognition. A conventional and sometimes successful approach to design APLs with enhanced 61 pMHC stability and immunogenicity has been to optimize interactions between peptide anchor 62 residues and MHC binding pockets [17] [18] [19] . However, escape variants that target TCR recognition 63 often exhibit optimal MHC anchor residues, reducing possibilities for such modifications. 64 Optimally, the introduced modifications should also not alter the conformation of APLs compared 65 to the original epitopes, in order to elicit efficient cross-reactive CTL responses towards the wild- 66 type epitope [18, 20, 21] . Therefore, the design of a novel generation of APLs that could promote 67 such responses would represent a crucial step towards the development of efficient anti-viral T-68 cell based vaccines [22] .
69 70 We have previously demonstrated that the immunogenicity of the cancer-associated H-2D b -71 restricted antigen gp10025-33 [23] or the T cell epitope associated with impaired peptide processing 72 (TEIPP) neo-epitope Thr4 [24-26] was dramatically improved following substitution of peptide 73 position 3 to a proline (p3P). Comparative structural analyses revealed that the conformation of 74 the APLs was similar to wild-type epitopes, and that the stabilizing effect of p3P is accounted for 75 by van der Waals and CH-π interactions with the H-2D (Table S1) (Fig. 4A) . In contrast to gp33, the p2-p4 section is more constrained in both V3P and PF, 223 following TCR binding ( Fig. 4B, 4C ). However, it should be noted that the final conformations of 224 all three peptides in the ternary complexes is nearly identical (Fig. 4D ). In conclusion, residues 1 225 and 6 in p3P-APLs take the same conformations prior to TCR binding as found in the ternary 226 complexes, potentially enabling a more favorable surface for P14 TCR binding. before TCR binding ( Fig. 4, 5) . Altogether, p1K, P6F and heavy chain residues R62, H155 and 242 E163 have already adopted in the unbound V3P and PF complexes similar conformations to those 243 observed in all three ternary structures ( Fig. 4, 5) . Thus, the p3P substitution potentially facilitates 244 TCR recognition by positioning specific key peptide and MHC residues prior to the formation of 245 the ternary complexes. This is well in line with our SPR and ITC results, which indicate that the 246 energy required for P14 recognition of V3P is reduced compared to gp33 (Table 1 , Fig. S1 ). for each ternary structure with each TCR-unbound pMHC variant indicated an additional structural 317 reason for the increased TCR recognition of p3P-modified epitopes. In all cases, conformational 318 differences were observed in peptide residues p1K and p6F in PF and V3P, compared to Y4F and 319 gp33, before TCR binding. In all p3P cases, the side chains of peptide residues p1K and p6F took 320 the same conformation, as observed in the ternary structures, prior to TCR binding. In line with 321 this, others [33, 45] and we [37] have previously demonstrated the importance of residue p1K for 322 recognition by the TCR P14. The crystal structure of the semi-agonist Y4A (KAVANFATM) also 323 revealed a similar conformation for both p1K and p6F prior to binding to P14 TCR [37] . 324 Furthermore, the conformation of the MHC "TCR footprint" heavy chain residues R62, H155 and 325 E163 [46, 47] was also affected following p3P substitution, possibly due to the movements of p1K 326 and p6F. Altogether, prior to TCR landing, the p3P modification alters the conformation of 327 residues both in the peptide and the MHC heavy chain similar to conformations taken upon binding 328 to the TCR, thus predisposing the pMHC for facilitated TCR recognition.
330
The results presented within this study indicate in our opinion that i) docking of P14 to p3P-331 modified peptides is facilitated since the conformations of key residues in both peptide and heavy 332 chain are already optimal prior to TCR binding (ready-to-go conformation); ii) consequently, the 333 energetic costs for TCR recognition should be reduced since there is no need for any major 334 movement in the rigidified epitope besides the conformational change for residue p4Y. As 335 vaccination with PF restored endogenous T cell recognition of Y4F, the p3P modification could 336 thus represent a novel way to increase the immunogenicity of a large array of H-2D b -restricted 337 epitopes as well as possibly viral epitopes restricted by other MHC alleles. We thus describe here 338 a successful approach to restore recognition of viral escape peptide that can be easily coupled to 339 already existing vaccination protocols, including vaccination with full-length proteins as well as 340 e.g. modified mRNA vaccines, by introducing the p3P modification in a selection of viral epitopes. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/862144 doi: bioRxiv preprint 
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Figure Legends
